The effect of β-blockers on bone metabolism as potential drugs under investigation for osteoporosis and fracture healing

Expert Opinion on Investigational Drugs

Volumn 17, Issue 9, 2008, Pages 1281-1299

  Graham, Simon ^a   Hammond Jones, Dafydd ^a   Gamie, Zakareya ^a   Polyzois, Ioannis ^a   Tsiridis, Evgenios ^b   Tsiridis, Eleftherios ^a  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

^b Cardio Thoracic Anaesthetic Unit   (Greece)

Author keywords

Adrenergic system; Blockers; Fracture healing; Leptin; Sympathetic nervous system

Indexed keywords

ATENOLOL; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CALCIUM CHANNEL BLOCKING AGENT; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESTROGEN; GLUCOCORTICOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEPTIN; METOPROLOL; PHENTOLAMINE; PROPRANOLOL; SOTALOL; THIAZIDE DIURETIC AGENT;

ACUTE HEART INFARCTION; ADIPOCYTE; ADRENERGIC RECEPTOR BLOCKING; ADRENERGIC SYSTEM; BODY MASS; BONE DENSITY; BONE MASS; BONE METABOLISM; BONE MINERALIZATION; BONE REMODELING; CARDIOVASCULAR DISEASE; CELL ACTIVITY; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL TRIAL; CYTOKINE PRODUCTION; DISEASE COURSE; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG RESEARCH; DUAL ENERGY X RAY ABSORPTIOMETRY; FRACTURE HEALING; FRAGILITY FRACTURE; HORMONE ACTION; HORMONE DETERMINATION; HUMAN; HYPERTENSION; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; NONHUMAN; OBESITY; OSSIFICATION; OSTEOBLAST; OSTEOLYSIS; OSTEOPOROSIS; OVARIECTOMY; PATHOGENESIS; POSTMENOPAUSE; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; RISK REDUCTION; SIGNAL TRANSDUCTION;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; DRUG EVALUATION, PRECLINICAL; FRACTURE HEALING; HUMANS; OSTEOPOROSIS; SYMPATHETIC NERVOUS SYSTEM;

EID: 52949115340     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.17.9.1281     Document Type: Review

References (83)

1. Koch WJ, Lefkowitz RJ, Rockman HA. Functional consequences of altering myocardial adrenergic receptor signaling. Ann Rev Physiol 2000;62:237-60
2. Xiao RP, Avdonin P, Zhou YY, et al. Coupling of beta2-adrenoceptor to Gi proteins and its physiological relevance in murine cardiac myocytes. Circ Res 1999;84(1):43-52
3. Rodan SB, Rodan GA. Parathyroid hormone and isoproterenol stimulation of adenylate cyclase in rat osteosarcoma clonal cells. Hormone competition and site heterogeneity. Biochim Biophys Acta 1981;673(1):46-54
4. Pasco JA, Henry MJ, Sanders KM, et al. Beta-adrenergic blockers reduce the risk of fracture partly by increasing bone mineral density: Geelong Osteoporosis Study. J Bone Miner Res 2004;19(1):19-24
5. Tanko LB, Christiansen C, Cox DA, et al. Relationship between osteoporosis and cardiovascular disease in postmenopausal women. J Bone Miner Res 2005;20(11):1912-20
6. Dorian P. Antiarrhythmic action of beta-blockers: potential mechanisms. J Cardiovasc Pharmacol Ther 2005;10 (Suppl 1):S15-22
7. Flannery G, Gehrig-Mills R, Billah B, Krum H. Analysis of randomized controlled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving beta-blockers. Am J Cardiol 2008;101(6):865-9
8. Moore RE, Smith CK II, Bailey CS, et al. Characterization of beta-adrenergic receptors on rat and human osteoblast-like cells and demonstration that beta-receptor agonists can stimulate bone resorption in organ culture. Bone Miner 1993;23(3):301-15
9. Takeda S, Elefteriou F, Levasseur R, et al. Leptin regulates bone formation via the sympathetic nervous system. Cell 2002;111(3):305-17
10. Metra M, Dei Cas L, Cleland J. Pharmacokinetic and pharmacodynamic characteristics of β-blockers: when differences may matter. J Card Fail 2006;12(3):177-81
11. Raisz LG. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest 2005;115(12):3318-25
12. Poole KE, Compston JE. Osteoporosis and its management. BMJ 2006;333(7581):1251-6
13. Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures. Lancet 2002;359(9319):1761-7
14. Reginster JY, Burlet N. Osteoporosis: a still increasing prevalence. Bone 2006;38(2 Suppl 1):S4-9
15. Riggs BL, Melton LJ 3rd. Involutional osteoporosis. N Engl J Med 1986;314(26):1676-86
16. Takeda S, Karsenty G. Central control of bone formation. J Bone Miner Metab 2001;19(3):195-8
17. Pacifici R. Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis. J Bone Miner Res 1996;11(8):1043-51
18. Guney E, Kisakol G, Ozgen G, et al. Effect of weight loss on bone metabolism: comparison of vertical banded gastroplasty and medical intervention. Obes Surg 2003;13(3):383-8
19. Wardlaw GM. Putting body weight and osteoporosis into perspective. Am J Clin Nutr 1996;63(3 Suppl):S433-6
20. Kameda T, Mano H, Yuasa T, et al. Estrogen inhibits bone resorption by directly inducing apoptosis of the bone-resorbing osteoclasts. J Exp Med 1997;186(4):489-95
21. Ducy P, Amling M, Takeda S, et al. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 2000;100(2):197-207
22. Hamrick MW, Ferrari SL. Leptin and the sympathetic connection of fat to bone. Osteoporos Int 2008;19(7):905-12
23. Cirmanova V, Bayer M, Starka L, Zajickova K. The effect of leptin on bone - an evolving concept of action. Physiol Res 2008;57(Suppl 1):S143-51
24. Elmquist JK, Strewler GJ. Physiology: do neural signals remodel bone? Nature 2005;434(7032):447-8
25. Considine RV, Sinha MK, Heiman ML, et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 1996;334(5):292-5
26. Thomas T. The complex effects of leptin on bone metabolism through multiple pathways. Curr Opin Pharmacol 2004;4(3):295-300
27. Baldock PA, Sainsbury A, Couzens M, et al. Hypothalamic Y2 receptors regulate bone formation. J Clin Invest 2002;109(7):915-21
28. Cornish J, Callon KE, Bava U, et al. Leptin directly regulates bone cell function in vitro and reduces bone fragility in vivo. J Endocrinol 2002;175(2):405-15
29. Steppan CM, Crawford DT, Chidsey-Frink KL, et al. Leptin is a potent stimulator of bone growth in ob/ob mice. Regul Pept 2000;92(1-3):73-8
30. Bagnasco M, Dube MG, Katz A, et al. Leptin expression in hypothalamic PVN reverses dietary obesity and hyperinsulinemia but stimulates ghrelin. Obes Res 2003;11(12):1463-70
31. Holloway WR, Collier FM, Aitken CJ, et al. Leptin inhibits osteoclast generation. J Bone Miner Res 2002;17(2):200-9
32. Thomas T, Gori F, Khosla S, et al. Leptin acts on human marrow stromal cells to enhance differentiation to osteoblasts and to inhibit differentiation to adipocytes. Endocrinology 1999;140(4):1630-8
33. Amling M, Takeda S, Karsenty G. A neuro (endo)crine regulation of bone remodeling. Bioessays 2000;22(11):970-5
34. Karsenty G. Leptin controls bone formation through a hypothalamic relay. Recent Prog Horm Res 2001;56:401-15
35. Lorentzon R, Alehagen U, Boquist L. Osteopenia in mice with genetic diabetes. Diabetes Res Clin Pract 1986;2(3):157-63
36. Schilling A, Holzmann T, Rueger J, Karsenty G. Leptin regulates bone mass in rats. Bone 2001;(S88):OR74
37. Foldes J, Shih MS, Levy J. Bone structure and calcium metabolism in obese Zucker rats. Int J Obes Relat Metab Disord 1992;16(2):95-102
38. Mathey J, Horcajada-Molteni MN, Chanteranne B, et al. Bone mass in obese diabetic Zucker rats: influence of treadmill running. Calcif Tissue Int 2002;70(4):305-11
39. Hamrick MW, Pennington C, Newton D, et al. Leptin deficiency produces contrasting phenotypes in bones of the limb and spine. Bone 2004;34(3):376-83
40. Khan S, Lee M, DuRaine G, Reddi H. The role of leptin in the local control of fracture healing. 54th Annual Meeting of the Orthopaedic Research Society; 2008; San Francisco, California
41. Hohmann EL, Elde RP, Rysavy JA, et al. Innervation of periosteum and bone by sympathetic vasoactive intestinal peptide-containing nerve fibers. Science 1986;232(4752):868-71
42. Schoppet M, Preissner KT, Hofbauer LC. RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function. Arterioscler Thromb Vasc Biol 2002;22(4):549-53
43. Takeuchi T, Tsuboi T, Arai M, Togari A. Adrenergic stimulation of osteoclastogenesis mediated by expression of osteoclast differentiation factor in MC3T3-E1 osteoblast-like cells. Biochem Pharmacol 2001;61(5):579-86
44. Kondo A, Mogi M, Koshihara Y, Togari A. Signal transduction system for interleukin-6 and interleukin-11 synthesis stimulated by epinephrine in human osteoblasts and human osteogenic sarcoma cells. Biochem Pharmacol 2001;61(3):319-26
45. Kondo A, Togari A. In vivo stimulation of sympathetic nervous system modulates osteoblastic activity in mouse calvaria. Am J Physiol Endocrinol Metab 2003;285(3):E661-7
46. Morinaga Y, Fujita N, Ohishi K, Tsuruo T. Stimulation of interleukin-11 production from osteoblast-like cells by transforming growth factor-beta and tumor cell factors. Int J Cancer 1997;71(3):422-8
47. Hughes FJ, Howells GL. Interleukin-11 inhibits bone formation in vitro. Calcif Tissue Int 1993;53(5):362-4
48. Hughes FJ, Howells GL. Interleukin-6 inhibits bone formation in vitro. Bone Miner 1993;21(1):21-8
49. Hakeda Y, Yoshino T, Natakani Y, et al. Prostaglandin E2 stimulates DNA synthesis by a cyclic AMP-independent pathway in osteoblastic clone MC3T3-E1 cells. J Cell Physiol 1986;128(2):155-61
50. Cherruau M, Facchinetti P, Baroukh B, Saffar JL. Chemical sympathectomy impairs bone resorption in rats: a role for the sympathetic system on bone metabolism. Bone 1999;25(5):545-51
51. Cherruau M, Morvan FO, Schirar A, Saffar JL. Chemical sympathectomy-induced changes in TH-, VIP-, and CGRP-immunoreactive fibers in the rat mandible periosteum: influence on bone resorption. J Cell Physiol 2003;194(3):341-8
52. Hill EL, Turner R, Elde R. Effects of neonatal sympathectomy and capsaicin treatment on bone remodeling in rats. Neuroscience 1991;44(3):747-55
53. Elefteriou F, Ahn JD, Takeda S, et al. Leptin regulation of bone resorption by the sympathetic nervous system and CART. Nature 2005;434(7032):514-20
54. Pierroz D, Muzzin P, Glatt V. β1 β2-adrenergic receptor ko mice have decreased total body and cortical bone mass despite increased trabecular bone number J Bone Miner Res 2004;19(Suppl 1):1121
55. Pierroz DD, Bouxsein ML, Rizzoli R, Ferrari SL. Combined treatment with a beta-blocker and intermittent PTH improves bone mass and microarchitecture in ovariectomized mice. Bone 2006;39(2):260-7
56. Dhillon H, Glatt V, Ferrari S, Bouxsein ML. Beta-adrenergic receptor KO mice have increased bone mass and strength but are not protected from ovariectomy-induced bone loss. J Bone Miner Res 2004;19(Suppl 1):S32
57. Pierroz D, Bouxsein ML, Muzzin P. Bone loss following ovariectomy is maintained in absence of adrenergic receptor β1 and β2 signaling. J Bone Miner Res 2005;19(Suppl 1):S277
58. Marenzana M, De Souza RL, Chenu C. Blockade of beta-adrenergic signaling does not influence the bone mechano-adaptive response in mice. Bone 2007;41(2):206-15
59. Zeman RJ, Hirschman A, Hirschman ML, et al. Clenbuterol, a beta 2-receptor agonist, reduces net bone loss in denervated hindlimbs. Am J Physiol 1991;261(2 Pt 1):E285-9
60. Sandhu HS, Herskovits MS, Singh IJ. Effect of surgical sympathectomy on bone remodeling at rat incisor and molar root sockets. Anat Rec 1987;219(1):32-8
61. Pagani F, Sibilia V, Cavani F, et al. Sympathectomy alters bone architecture in adult growing rats. J Cell Biochem 2008;104(6):2155-64
62. Bonnet N, Laroche N, Vico L, et al. Dose effects of propranolol on cancellous and cortical bone in ovariectomized adult rats. J Pharmacol Exp Ther 2006;318(3):1118-27
63. Henry MJ, Pasco JA, Nicholson GC, et al. Prevalence of osteoporosis in Australian women: Geelong Osteoporosis Study. J Clin Densitom 2000;3(3):261-8
64. Ferrari SL, Demissie S, Karasik D, et al. Beta 2 adrenergic receptor, beta-blockers and their influence on bone mass in humans: the Framingham osteoporosis study. J Bone Miner Res 2005;20(Suppl 1):S11
65. Bonnet N, Gadois C, McCloskey E, et al. Protective effect of beta blockers in postmenopausal women: influence on fractures, bone density, micro and macroarchitecture. Bone 2007;40(5):1209-16
66. Rejnmark L, Vestergaard P, Kassem M, et al. Fracture risk in perimenopausal women treated with beta-blockers. Calcif Tissue Int 2004;75(5):365-72
67. Reid IR, Gamble GD, Grey AB, et al. Beta-blocker use, BMD, and fractures in the study of osteoporotic fractures. J Bone Miner Res 2005;20(4):613-8
68. Levasseur R, Dargent-Molina P, Sabatier JP, et al. Beta-blocker use, bone mineral density, and fracture risk in older women: results from the Epidemiologie de l'Osteoporose prospective study. J Am Geriatr Soc 2005;53(3):550-2
69. Reid IR, Lucas J, Wattie D, et al. Effects of a beta-blocker on bone turnover in normal postmenopausal women: a randomized controlled trial. J Clin Endocrinol Metab 2005;90(9):5212-6
70. Majeska RJ, Minkowitz B, Bastian W, Einhorn TA. Effects of beta-adrenergic blockade in an osteoblast-like cell line. J Orthop Res 1992;10(3):379-84
71. Tsiridis E, Upadhyay N, Giannoudis P. Molecular aspects of fracture healing: which are the important Molecules? Injury 2007;38(Suppl 1):S11-25
72. Berg RA, Moss J, Baum BJ, Crystal RG. Regulation of collagen production by the beta-adrenergic-system. J Clin Invest 1981;67(5):1457-62
73. Minkowitz B, Boskey AL, Line JM, et al. Effects of propranolol on bone metabolism in the rat. J Orthop Res 1991;9(6):869-75
74. Rejnmark L, Vestergaard P, Mosekilde L. Treatment with beta-blockers, ACE inhibitors, and calcium-channel blockers is associated with a reduced fracture risk: a nationwide case-control study. J Hypertens 2006;24(3):581-9
75. Meisinger C, Heier M, Lang O, Doring A. Beta-blocker use and risk of fractures in men and women from the general population: the MONICA/KORA Augsburg cohort study. Osteoporos Int 2007;18(9):1189-95
76. Schlienger RG, Kraezlin ME, Jick SS, Meier CR. Use of beta-blockers and risk of fractures. JAMA 2004;292(11):1326-32
77. de Vries F, Souverein PC, Cooper C, et al. Use of beta-blockers and the risk of hip/femur fracture in the United Kingdom and The Netherlands. Calcif Tissue Int 2007;80(2):69-75
78. Perez-Castrillon JL, Vega G, Abad L, et al. Effect of beta-blockers on bone mass and biomechanical parameters of the femoral neck in males with acute myocardial infarction. Joint Bone Spine 2007;74(3):259-62
79. Bauer DC. HMG CoA reductase inhibitors and the skeleton: a comprehensive review. Osteoporos Int 2003;14(4):273-82
80. Jamal SA, Browner WS, Bauer DC, Cummings SR. Intermittent use of nitrates increases bone mineral density: the study of osteoporotic fractures. J Bone Miner Res 1998;13(11):1755-9
81. Reid IR, Ames RW, Orr-Walker BJ, et al. Hydrochlorothiazide reduces loss of cortical bone in normal postmenopausal women: a randomized controlled trial. Am J Med 2000;109(5):362-70
82. Chenu C, Marenzana M. Sympathetic nervous system and bone remodeling. Joint Bone Spine 2005;72(6):481-3
83. Griffin SC, Barber JA, Manca A, et al. Cost effectiveness of clinically appropriate decisions on alternative treatments for angina pectoris: prospective observational study. BMJ 2007;334(7594):624